We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 117

Court denies Myriad’s request to enjoin sale of rival BRCA1BRCA2 tests
  • Shook Hardy & Bacon LLP
  • USA
  • March 20 2014

A federal court in Utah has denied the request for a preliminary injunc- tion filed by Myriad Genetics against a rival company that offered tests


News bytes
  • Shook Hardy & Bacon LLP
  • USA
  • November 13 2014

The U.S. Food and Drug Administration (FDA) makes available Guidance for Industry and staff titled "Molecular Diagnostic Instruments with Combined


Court finds no standing for Consumer Watchdog in stem cell patent appeal
  • Shook Hardy & Bacon LLP
  • USA
  • June 12 2014

The Federal Circuit Court of Appeals has rejected not-for-profit Consumer Watchdog's appeal of the U.S. Patent and Trademark Office's (USPTO's


News bytes
  • Shook Hardy & Bacon LLP
  • USA
  • July 17 2014

The U.S. Food and Drug Administration issues guidance titled "Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal, Food


News bytes
  • Shook Hardy & Bacon LLP
  • USA
  • August 7 2014

The U.S. Patent & Trademark Office (USPTO) selects 19 law schools to join its Law School Clinic Certification Pilot Program. Four of the law schools


Analysts predicts biosimilars boom as biologics reach new patent cliff
  • Shook Hardy & Bacon LLP
  • Global
  • August 7 2014

A new Allied Market Research (AMR) report predicts that the global biosimilars market, which accounted for $1.3 billion in 2013, will generate $35


News Bytes
  • Shook Hardy & Bacon LLP
  • USA
  • February 13 2014

The U.S. Patent and Trademark Office requests comments by March 3, 2014, on the revision of a previously approved information collec- tion concerning


News bytes
  • Shook Hardy & Bacon LLP
  • USA
  • October 30 2014

The U.S. Food and Drug Administration (FDA) makes available Guidance for Industry titled "Circumstances that Constitute Delaying, Denying, Limiting


Indian Supreme Court rules Novartis cancer drug change not patentable
  • Shook Hardy & Bacon LLP
  • India
  • April 4 2013

The Supreme Court of India has rejected the patent application filed by Novartis AG for a beta crystalline form of its cancer drug Gleevec, also


News Bytes - April 4, 2013
  • Shook Hardy & Bacon LLP
  • USA
  • April 4 2013

The U.S. Food and Drug Administration (FDA) issues draft guidance titled "Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors